Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

NCT07124819 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Knee
Venous Thromboembolism (VTE)
Prevention

Interventions

DRUG: Sodium enoxaparin
DRUG: Dimolegin
DRUG: Dimolegin placebo
DRUG: Sodium enoxaparine placebo

Sponsor

Avexima Diol LLC